These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 31509477

  • 1. New Frontiers in Osteoporosis Therapy.
    Cheng C, Wentworth K, Shoback DM.
    Annu Rev Med; 2020 Jan 27; 71():277-288. PubMed ID: 31509477
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New therapeutic targets for osteoporosis.
    Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG.
    Maturitas; 2019 Feb 27; 120():1-6. PubMed ID: 30583758
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Osteoporosis.
    Compston JE, McClung MR, Leslie WD.
    Lancet; 2019 Jan 26; 393(10169):364-376. PubMed ID: 30696576
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, Cozzolino M.
    J Nephrol; 2017 Oct 26; 30(5):677-687. PubMed ID: 28432640
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological Therapy of Osteoporosis: What's New?
    Iolascon G, Moretti A, Toro G, Gimigliano F, Liguori S, Paoletta M.
    Clin Interv Aging; 2020 Oct 26; 15():485-491. PubMed ID: 32273690
    [Abstract] [Full Text] [Related]

  • 13. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC, Wanderman N, Anderson PA, Freedman BA.
    Clin Interv Aging; 2020 Oct 26; 15():1023-1033. PubMed ID: 32636617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
    Anastasilakis AD, Yavropoulou MP, Palermo A, Makras P, Paccou J, Tabacco G, Naciu AM, Tsourdi E.
    Eur J Endocrinol; 2024 Jul 02; 191(1):R9-R21. PubMed ID: 38938063
    [Abstract] [Full Text] [Related]

  • 16. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A, Clements JN.
    Am J Health Syst Pharm; 2019 Jan 25; 76(3):130-135. PubMed ID: 30689744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M, Levancini M.
    Panminerva Med; 2014 Jun 25; 56(2):115-31. PubMed ID: 24942322
    [Abstract] [Full Text] [Related]

  • 20. Treatment of osteoporosis: whom, how and for how long?
    Dede AD, Callan M.
    Br J Hosp Med (Lond); 2018 May 02; 79(5):259-264. PubMed ID: 29727238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.